AnaptysBio shares fell 10% premarket after the company sued GSKs Tesaro again, alleging new violations of their 2014 collaboration agreement involving PD-1 trial participation. Anaptys said it attempted to resolve the dispute before Tesaro initiated its own lawsuit. A trial is expected in July 2026, and milestone and royalty payments to Anaptys will continue during the process.